ILTS Trademark

Trademark Overview

On Monday, February 27, 2017, a trademark application was filed for ILTS with the United States Patent and Trademark Office. The USPTO has given the ILTS trademark a serial number of 79210847. The federal status of this trademark filing is CANCELLED - SECTION 71 as of Friday, November 1, 2024. This trademark is owned by MEDRX CO., LTD. The ILTS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations used for transdermal application of a wide variety of therapeutic agents, namely, a transdermal drug delivery system which improves skin permeation of the therapeutic agents

General Information

Serial Number79210847
Word MarkILTS
Filing DateMonday, February 27, 2017
Status709 - CANCELLED - SECTION 71
Status DateFriday, November 1, 2024
Registration Number5445592
Registration DateTuesday, April 17, 2018
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 30, 2018

Trademark Statements

Goods and ServicesPharmaceutical preparations used for transdermal application of a wide variety of therapeutic agents, namely, a transdermal drug delivery system which improves skin permeation of the therapeutic agents

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, November 1, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameMEDRX CO., LTD
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressJP
Party NameMEDRX CO., LTD
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressJP
Party NameMEDRX CO., LTD
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressJP

Trademark Events

Event DateEvent Description
Thursday, June 29, 2017SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, June 30, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, July 6, 2017NON-FINAL ACTION WRITTEN
Friday, July 7, 2017NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, August 4, 2017REFUSAL PROCESSED BY IB
Friday, October 27, 2017ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, June 30, 2017ASSIGNED TO EXAMINER
Tuesday, July 4, 2017APPLICATION FILING RECEIPT MAILED
Saturday, July 15, 2017REFUSAL PROCESSED BY MPU
Saturday, July 15, 2017NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, October 27, 2017TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, December 14, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, January 10, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, January 10, 2018NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, January 10, 2018NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Saturday, January 27, 2018NOTIFICATION PROCESSED BY IB
Tuesday, January 30, 2018PUBLISHED FOR OPPOSITION
Tuesday, January 30, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 17, 2018REGISTERED-PRINCIPAL REGISTER
Thursday, December 14, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, December 15, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, December 18, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, July 17, 2018FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Wednesday, August 1, 2018FINAL DISPOSITION NOTICE SENT TO IB
Monday, April 17, 2023COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, November 1, 2024CANCELLED SECTION 71
Thursday, September 20, 2018NEW REPRESENTATIVE AT IB RECEIVED
Wednesday, August 1, 2018FINAL DISPOSITION PROCESSED
Friday, August 31, 2018FINAL DECISION TRANSACTION PROCESSED BY IB

Related Keywords

ilts therapeutic transdermal agents system delivery which improves permeation skin drug